Navigation Links
Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts

PITTSBURGH, June 30 /PRNewswire/ -- Precision Therapeutics, a life-science company known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, continues to gain ground in novel genomic testing and bioinformatics research.  

Precision Therapeutics has recently recruited key scientific research experts, biostatisticians and medical specialists to support their development efforts. "I think Precision is addressing a very important clinical question, using a unique scientific approach that holds high potential to realizing personalized medicine," states Shuguang Huang, Ph.D., newly appointed Director of Bioinformatics at Precision. Huang is the former Director of Discovery Biostatistics and Translational Medicine for Wyeth Research, and was previously a Senior Research Scientist for Eli Lilly and Co.

It is Precision's dedication to ongoing research and clinical trials that has attracted top-level physicians and research scientists. Chunqiao Tian, Ph.D., was also recruited to join the company as the Director of Biostatistics. "I came to Precision because I believe that individualized therapy is the future of cancer treatment, and this company plays a leading role in that field," states Dr. Tian.   Tian was an International Visiting Scholar and leading biostatistician with the Gynecologic Oncology Group (GOG), a non-profit clinical and scientific research organization in the field of gynecologic malignancies.

The clinical trials team at Precision has been augmented with the addition of Hong Ma, M.D., a medical oncologist and expert in Phase I-IV clinical trials.  Dr. Ma comes to Precision with 16 years of experience in clinical trials with a focus in oncology, medical devices and drug development.

Precision is actively developing multi-genomic predictors of patient response to cancer therapy. State-of-the-art bioinformatics combined with the company's proprietary live tissue platform provides a unique foundation and methodology for development and commercialization of these novel predictive markers for cancer therapy.  Early validation data presented at AACR 2010 shows promising results for novel multi-gene predictors currently in development.

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. ChemoFx® has shown positive outcomes in patient survival rates while significantly lowering healthcare costs when a physician chooses a therapy deemed responsive by the marker.  

Precision Therapeutics, led by CEO Sean McDonald, has tripled its number of employees in a little over 3 years, and plans to open a second clinical laboratory in the Lawrenceville sector of Pittsburgh in July, 2010.  

For more information, please visit or

SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stretching single molecules allows precision studies of interacting electrons
2. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
3. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
4. New statistical technique improves precision of nanotechnology data
5. Precision Stability Storage Announces Upcoming Expansion
6. NISTs LIDAR may offer peerless precision in remote measurements
7. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
8. AMDL, Inc. Signs First Customer Agreement With Precision Diagnostic Laboratory for DR-70 (FDP) Cancer Test
9. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
10. Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes
11. SACHEM Launches 2-D HPLC e-Learning Program : New e-Learning Program Teaches Scientists How to Better Analyze and Prove Product Purity Through Greater Sensitivity and Precision in Identification of Trace Components
Post Your Comments:
(Date:10/13/2015)... SUNNYVALE, Calif. , Oct. 13, 2015  Cepheid ... the quarter ending September 30, 2015. ... financial results, total revenue for the third quarter of ... net loss per share is expected to be approximately ... financial results, non-GAAP net loss per share for the ...
(Date:10/13/2015)... Research and Markets( ) has announced ... for Bone Morphogenetic Protein Growth Factor Therapy - 16 ... --> --> Bone morphogenetic proteins ... bone after a fracture. In nature, these proteins have ... of the skeleton. There are twenty different BMPs that ...
(Date:10/13/2015)... ... October 13, 2015 , ... AxioMx ... that it has received a Phase I Small Business Innovative Research (SBIR) grant ... of General Medical Sciences (NIGMS), will fund the development of a technique to ...
(Date:10/13/2015)... 13, 2015  According to Kalorama Information, the ... $102 billion by the end of 2015. Clinical ... industry, as it is estimated that approximately 80% ... tests. In addition to diagnosing patients, clinical lab ... progression, monitor drug treatment and conditions, and determine ...
Breaking Biology Technology:
(Date:9/29/2015)... 2015 News facts: ... saving energy , Minimized design shrinks PC footprint ... Mode and embedded Fujitsu PalmSecure authentication enable enterprises to ... today shows that good things come in small packages, ... its enterprise desktop and mobile portfolio. Featuring workplace design ...
(Date:9/28/2015)... 2015 CLEAR, the leading biometric ... traveler service is coming to Austin-Bergstrom International ... a frictionless experience, serious speed and enhanced ... offers our travelers an expedited security screening ... Jim Smith , Executive Director, Austin-Bergstrom International ...
(Date:9/28/2015)... 28, 2015 The global ... USD 12.03 billion by 2020, growing at a CAGR ... as Backside Illumination (BSI) technique to improve picture quality ... period.      (Logo: , ... to reduce loss and, thus, reduce the noise interference ...
Breaking Biology News(10 mins):